Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
about
Ebolavirus comparative genomicsArms Race between Enveloped Viruses and the Host ERAD MachineryInterferon-γ Inhibits Ebola Virus InfectionMinimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig ModelBoth Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like DomainEbola virus - from neglected threat to global emergency state.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography.Impact of spatial dispersion, evolution, and selection on Ebola Zaire Virus epidemic wavesDeep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells.A strategy for O-glycoproteomics of enveloped viruses--the O-glycoproteome of herpes simplex virus type 1Possible FDA-approved drugs to treat Ebola virus infectionEbola virus entry: a curious and complex series of events.The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.Flavivirus and Filovirus EvoPrinters: New alignment tools for the comparative analysis of viral evolution.Influenza A Virus-Induced Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication.Characterization of Human and Murine T-Cell Immunoglobulin Mucin Domain 4 (TIM-4) IgV Domain Residues Critical for Ebola Virus Entry.Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus.Human Adaptation of Ebola Virus during the West African Outbreak.The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.Ebola virus entry into host cells: identifying therapeutic strategies.Viral O-GalNAc peptide epitopes: a novel potential target in viral envelope glycoproteins.Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus.The roles of ebolavirus glycoproteins in viral pathogenesis.Strategies to induce broadly protective antibody responses to viral glycoproteins.Host Factors Involved in Ebola Virus Replication.Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice.Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function.Mechanisms of Filovirus Entry.Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs.Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap
P2860
Q26801790-EA96571E-74AC-4589-A9DF-7F5B57183B7FQ28078319-56B04122-C0FD-4A8A-9038-D390CABB9877Q28550929-191C2A11-7CE3-47E1-A143-51BD0C315D0DQ28553683-903253FA-380F-4C9F-A49B-972CE39E4B7AQ28596689-8325E0AA-3186-489F-B57E-90AB980FE53EQ30245153-A25B808F-AF33-44D0-B3F3-482461026DEAQ30252022-5042FC62-F442-4B2B-BFE3-5428D85BA5B1Q30409973-6CC41337-10C2-4B38-BE08-67599A840E34Q30650455-ADB1BB4C-A67D-4D10-A89A-B955FEE3B433Q34461912-8FB5ECE6-65C5-4C89-8EC0-0FBDB134BB79Q35242303-DBC09E5A-01F5-444B-B58E-5C033210480CQ35609603-18EAA7CA-6B35-458C-BA6E-C5E8B6F6056CQ35619456-18F9B8D9-C294-4011-B594-AA929750E330Q36043248-5AA9D0AD-9B78-4127-96DC-0A0C607E4BBAQ36407374-A254A4D8-7754-47E4-8656-CDD825302618Q36524003-23983306-4BE7-4472-A68E-6D82348DC5F0Q37002542-DF31F54A-5600-4121-9891-7C0EF07B2CF3Q37065966-04F90D54-AF0E-42F7-996B-C63E3AC6B0FCQ37402042-C1F71CCE-004D-4335-BB56-665D36467773Q37448307-2F07E26F-3C44-42A1-9508-9A635E520B45Q38618148-F0360F57-801D-446F-8606-65C31C704DD6Q38622432-AE5D32D3-CCF1-479C-9171-672BB5B7AF4FQ38785688-836BC1EA-E21E-4749-87AE-19B2F3B02A44Q38878292-6692FBAC-9674-4363-91B9-00790425D9BFQ39010678-4B182056-866C-45E2-9736-193D7C6E6D56Q39170802-4B8CF981-EAAE-4EE2-A84D-E5ECBB33DD3FQ39436358-CD65A209-4E90-4C1C-B199-A278EBF2FC68Q40052567-477565D1-5278-404B-9F83-AE2766D7CEFCQ40068996-4C62AF6D-05F6-4BFF-8877-22D9060B44D0Q40164611-65208848-4244-4863-915E-263E1E022A4AQ47551825-8EF21920-EF17-4A17-8917-7352B2CD4F2FQ47558474-B1D529F4-1280-4AE8-B33E-B33F212A1ECDQ56999931-728DA537-30AC-41F6-9009-FF549D5D6771
P2860
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
@en
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
@nl
type
label
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
@en
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
@nl
prefLabel
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
@en
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
@nl
P2093
P2860
P50
P356
P1433
P1476
Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
@en
P2093
Kartik Chandran
Nicholas J Lennemann
Wendy Maury
P2860
P304
P356
10.1128/MBIO.00862-13
P577
2014-01-28T00:00:00Z